MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 01-26-2023
Myovant Sciences Ltd. Operating Cash Flow 2011-2026 | MYOV
Annual Operating Cash Flow Myovant Sciences Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 371 M | -221 M | -224 M | -117 M | -18.2 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 371 M | -224 M | -42 M |
Quarterly Operating Cash Flow Myovant Sciences Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -170 M | -66.9 M | - | - | -168 M | -76.6 M | - | - | 464 M | -111 M | -62 M | - | -202 M | -135 M | -66.8 M | - | -171 M | -109 M | - | - | - | -26.6 M | - | - | -7.55 M | -687 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 464 M | -202 M | -60.6 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.85 | 3.24 % | $ 9.26 B |  Australia |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
524 M | $ 322.18 | -3.36 % | $ 42.2 B | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Burford Capital Limited
BUR
|
181 M | $ 4.71 | -0.53 % | $ 766 M |  Britain |
 |
Cabaletta Bio
CABA
|
-131 M | $ 3.51 | 3.09 % | $ 353 M | USA |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
-82.5 M | $ 7.72 | 4.04 % | $ 76.3 M | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M |  Israel |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
-55.2 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-6.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
156 M | $ 22.0 | 1.48 % | $ 1.03 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-72.5 M | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 101.75 | 2.29 % | $ 27.2 B | Germany |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.07 | -3.15 % | $ 5.05 M | Israel |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
Galectin Therapeutics
GALT
|
-23.9 M | $ 2.25 | -12.11 % | $ 144 M | USA |
 |
ContraFect Corporation
CFRX
|
-46 M | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
68 M | $ 1.38 | -10.97 % | $ 355 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Grifols, S.A.
GRFS
|
597 M | $ 8.6 | -1.04 % | $ 6.83 B |  Spain |
 |
Aquestive Therapeutics
AQST
|
-52.4 M | $ 4.28 | 0.94 % | $ 458 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 23.69 | -3.64 % | $ 3.01 B | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-284 M | $ 1.59 | 6.71 % | $ 423 M | Britain |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
-31.1 M | - | - | $ 169 M | USA |
|
Immatics N.V.
IMTX
|
-81.8 M | $ 10.8 | -1.86 % | $ 679 M | Germany |
 |
Caladrius Biosciences
CLBS
|
-19.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
-18.1 M | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
-211 M | $ 33.63 | -0.72 % | $ 2.23 B | USA |